From Bench to Kit: How a Biomarker Assay Becomes a Diagnostic Product

It starts with a question

Every diagnostic method begins with a clinical or scientific question: can we reliably measure this biomarker from this sample type, at the required sensitivity, with sufficient precision for clinical decision-making? At Masdiag, method development typically starts with literature review and feasibility assessment, followed by initial method design using the most appropriate analytical platform — whether LC-MS/MS, GC-FID, ELISA, CLIA, or another technique.

Development and optimisation

The development phase involves systematic optimisation of every parameter: sample extraction conditions, chromatographic separation, detection parameters, internal standard selection, and calibration strategy. For dried blood spot methods, additional factors come into play — haematocrit effects, spot homogeneity, extraction efficiency from filter paper, and stability during storage and transit.

This iterative process typically requires months of work, dozens of experiments, and deep analytical chemistry expertise.

Validation: proving it works

Method validation is where scientific rigour meets regulatory requirement. A fully validated method must demonstrate acceptable performance across multiple criteria: accuracy and precision (intra-day and inter-day), linearity and range, sensitivity (limit of detection and quantification), specificity (freedom from interference), recovery, and stability. For clinical methods, correlation studies against reference methods using patient samples are essential.

Masdiag follows international validation guidelines including ISO 15189, EMA, and FDA bioanalytical method validation standards.

From method to kit

Transitioning a validated laboratory method into a manufactured kit adds layers of complexity: raw material sourcing and quality control, manufacturing process design, lot-to-lot consistency, packaging, labelling, and shelf-life studies. Each kit must perform identically regardless of production batch — a standard that requires robust manufacturing processes and comprehensive quality systems.

Regulatory and market launch

Depending on the intended market, the kit may require IVD regulatory approval — CE marking for Europe, FDA clearance for the US, TGA listing for Australia, or other jurisdiction-specific pathways. This involves technical documentation, clinical evidence, quality management system audits, and ongoing post-market surveillance.

Masdiag handles the entire pipeline in-house — from initial R&D through validation, manufacturing, and regulatory submission — giving partners a single point of contact for the complete journey from concept to commercial product.